1. Home
  2. KN vs MESO Comparison

KN vs MESO Comparison

Compare KN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

HOLD

Current Price

$27.54

Market Cap

2.0B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.88

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KN
MESO
Founded
1946
2004
Country
United States
Australia
Employees
N/A
81
Industry
Consumer Electronics/Appliances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
KN
MESO
Price
$27.54
$16.88
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$22.33
N/A
AVG Volume (30 Days)
668.2K
166.7K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
118.94
N/A
EPS
0.50
N/A
Revenue
$593,200,000.00
N/A
Revenue This Year
$7.93
$633.98
Revenue Next Year
$8.28
$29.51
P/E Ratio
$54.54
N/A
Revenue Growth
7.17
N/A
52 Week Low
$12.19
$9.61
52 Week High
$27.73
$21.50

Technical Indicators

Market Signals
Indicator
KN
MESO
Relative Strength Index (RSI) 68.35 44.84
Support Level $26.58 $16.71
Resistance Level $27.57 $17.30
Average True Range (ATR) 1.00 0.49
MACD 0.08 -0.02
Stochastic Oscillator 91.26 43.82

Price Performance

Historical Comparison
KN
MESO

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: